Piramal Pharma Limited (NSE:PPLPHARMA)

Market Cap	181.30B -32.1%
Revenue (ttm)	88.71B -0.9%
Net Income	-1.64B
EPS	-1.24
Shares Out	1.33B
PE Ratio	n/a
Forward PE	82.54
Dividend	0.14 (0.10%)
Ex-Dividend Date	Jul 16, 2025

Volume	4,587,186
Average Volume	3,444,579
Open	141.01
Previous Close	143.56
Day's Range	136.05 - 142.95
52-Week Range	132.30 - 240.95
Beta	0.00
RSI	38.19
Earnings Date	May 14, 2026

About Piramal Pharma

Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, inje...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2020
• Employees: 5,476
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: PPLPHARMA

Financial Performance

In fiscal year 2025, Piramal Pharma's revenue was 91.51 billion, an increase of 11.99% compared to the previous year's 81.71 billion. Earnings were 911.30 million, an increase of 411.39%.